article thumbnail

Mapping the crisis: How data can help fix America’s growing pharmacy deserts

pharmaphorum

Skip to main content Thursday 12 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

article thumbnail

How AI and machine learning are transforming drug discovery

Pharmaceutical Technology

Free Whitepaper How value-based care is reshaping the life sciences This free white paper examines the benefits of value-based care (VBC) and how this translates into the wider life-sciences landscape. AI models can predict molecular interactions and assist in designing novel compounds tailored to specific therapeutic goals.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Juvenescence enhances AI drug discovery with Ro5 acquisition

Pharmaceutical Technology

Ro5’s AI Chemistry Platform also uses advanced machine learning models and cheminformatics tools for quick compound discovery and design from hit identification to lead optimisation. Juvenescence CBE and CEO Dr Richard Marshall stated: “We are delighted to welcome the Ro5 team and the company’s capabilities into Juvenescence.

article thumbnail

Hims & Hers shares plummet 35% as Novo Nordisk pulls partnership plug

Pharmaceutical Technology

Robert Barrie June 24, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Compounded GLP-1RA medication has become a key revenue driver for Hims & Hers’ telehealth platform. Hims & Hers’ revenue has been soaring on the back of its compounded glucagon-like peptide-1 receptor agonist (GLP-1RA) sales.

article thumbnail

Draig secures $140m for neuropsychiatric disorder therapies

Pharmaceutical Technology

These compounds have the potential for addressing a spectrum of neuropsychiatric disorders that currently lack adequate treatment options. As well as advancing DT-101, the new capital injection will also support the progression of two gamma-aminobutyric acid type A (GABA A ) receptor modulators towards clinical trials in 2026.

article thumbnail

5th Oligonucleotides for CNS Summit

pharmaphorum

Skip to main content Monday 14 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

article thumbnail

Novo Nordisk signs $812m research deal with Deep Apple for non-GLP-1 drugs

Pharmaceutical Technology

Novo Nordisk is eyeing a cardiometabolic drug market future that is not purely dominated by incretins, after signing a $812m partnership with Deep Apple Therapeutics to access novel compounds for obesity and other diseases.